Seelos Therapeutics (DB:NXE) - Stock Price, News & Analysis

NXE Stock Overview

NXE fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	2/6
Dividends	0/6

Rewards

Risk Analysis

Shares are highly illiquid

Negative shareholders equity

Shareholders have been substantially diluted in the past year

Does not have a meaningful market cap (€11M)

+ 2 more risks

Seelos Therapeutics, Inc. Competitors

Biofrontera

XTRA:B8F

€21.7m

SynBiotic

DUSE:SBX

€46.8m

Apontis Pharma

XTRA:APPH

€71.6m

Pierrel

DB:2FJ0

€92.8m

Price History & Performance

Summary of all time highs, changes and price drops for Seelos Therapeutics
Historical stock prices
Current Share Price	US$3.37
52 Week High	US$43.23
52 Week Low	US$3.26
Beta	1.86
1 Month Change	0%
3 Month Change	-22.91%
1 Year Change	-82.62%
3 Year Change	-95.24%
5 Year Change	-92.89%
Change since IPO	-96.76%

Recent updates

Shareholder Returns

	NXE	DE Pharmaceuticals	DE Market
7D	0%	-1.0%	-1.7%
1Y	-82.6%	-30.1%	1.4%

Return vs Industry: NXE underperformed the German Pharmaceuticals industry which returned -29.9% over the past year.

Return vs Market: NXE underperformed the German Market which returned 0.1% over the past year.

Price Volatility

Is NXE's price volatile compared to industry and market?
NXE volatility
NXE Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	7.0%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	9.8%
10% least volatile stocks in DE Market	2.4%

Stable Share Price: NXE's share price has been volatile over the past 3 months.

Volatility Over Time: Insufficient data to determine NXE's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2016	16	Raj Mehra	seelostherapeutics.com

Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company’s lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD). Its preclinical programs include SLS-007, a peptidic inhibitor to treat patients with PD; SLS-008 for the treatment of pediatric indications; SLS-004 for the treatment of PD; SLS-010, an H3 receptor antagonist; and SLS-012.

Seelos Therapeutics, Inc. Fundamentals Summary

How do Seelos Therapeutics's earnings and revenue compare to its market cap?
NXE fundamental statistics
Market cap	€10.47m
Earnings (TTM)	-€47.21m
Revenue (TTM)	€1.43m

8.8x

P/S Ratio

-0.3x

P/E Ratio

Is NXE overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
NXE income statement (TTM)
Revenue	US$1.55m
Cost of Revenue	US$0
Gross Profit	US$1.55m
Other Expenses	US$52.64m
Earnings	-US$51.09m

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	-3.73
Gross Margin	100.00%
Net Profit Margin	-3,295.87%
Debt/Equity Ratio	-55.5%

How did NXE perform over the long term?

See historical performance and comparison

NXE Stock Overview

Rewards

Risk Analysis

Seelos Therapeutics, Inc. Competitors

XTRA:B8F

€21.7m

DUSE:SBX

€46.8m

XTRA:APPH

€71.6m

DB:2FJ0

€92.8m

Price History & Performance

Recent News & Updates

Seelos Therapeutics, Inc. Provides Update on Top-Line Results from its Amyotrophic Lateral Sclerosis Study with SLS-005 (IV Trehalose)

Seelos Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $4.000001 million.

Seelos Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $4.000001 million.

Seelos Therapeutics, Inc. Announces Receipt of Minutes from its End of Phase II Meeting with the United States Food and Drug Administration Highlighting Modifications to the Primary and Secondary Endpoints of its Phase II Study of SLS-002

Founder recently bought €92k worth of stock

New major risk - Market cap size

Recent updates

Seelos Therapeutics, Inc. Provides Update on Top-Line Results from its Amyotrophic Lateral Sclerosis Study with SLS-005 (IV Trehalose)

Seelos Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $4.000001 million.

Seelos Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $4.000001 million.

Seelos Therapeutics, Inc. Announces Receipt of Minutes from its End of Phase II Meeting with the United States Food and Drug Administration Highlighting Modifications to the Primary and Secondary Endpoints of its Phase II Study of SLS-002

Founder recently bought €92k worth of stock

New major risk - Market cap size

Seelos Therapeutics, Inc. has completed a Follow-on Equity Offering.

Seelos Therapeutics, Inc. has filed a Follow-on Equity Offering.

New major risk - Shareholder dilution

New major risk - Revenue and earnings growth

Seelos Therapeutics Receives Non-Compliance Notice from Nasdaq Regarding Non-Compliance with Minimum Bid Price Requirement for Continued Listing on the Nasdaq Capital Market Under Nasdaq Listing Rule 5550(a)(2)

Seelos Therapeutics Receives Non-Compliance Notice From Nasdaq

Seelos Therapeutics, Inc. Announces Top Line Results from SLS-002 Phase II Study in Adults with Major Depressive Disorder at Imminent Risk of Suicide

Seelos Therapeutics, Inc. Announces the Close of Enrollment of Its Registration Directed Study of Sls-002 (Intranasal Racemic Ketamine) for Acute Suicidal Ideation and Behavior (Asib) in Adults with Major Depressive Disorder (MDD)

Listing Qualifications Staff of Nasdaq Provides Notice to Seelos Therapeutics for Not Regain Compliance with Rule 5550(a)(2) and Not Eligible for Second 180 Calendar Day Compliance Period

No longer forecast to breakeven

Seelos Therapeutics Announces Completion of Enrollment of its Phase II/III Trial of SLS-005 in Amyotrophic Lateral Sclerosis on the HEALEY ALS Platform

Seelos Therapeutics Doses First Patients in an Ethnobridging Study with Sls-002 (Intranasal Racemic Ketamine)

Seelos Therapeutics, Inc. Announces Data Demonstrating Downregulation of Alpha Synuclein in an In Vivo Gene Therapy Study of SLS-004 Utilizing CRISPR-dCas9 in Parkinson's Disease

Seelos Therapeutics Receives Written Notice of Non-Compliance from Nasdaq

Seelos Therapeutics Doses First Patient in A Registrational Phase II/III Study of SLS-005 in Spinocerebellar Ataxia

Seelos Therapeutics Inc. Receives A Research and Development Grant from the Michael J. Fox Foundation for Parkinson's Research for SLS-004

Seelos Therapeutics, Inc. Announces Data Demonstrating Statistically Significant Downregulation of mRNA and Reduction of Alpha Synuclein in Vitro Gene Therapy Study

Seelos Therapeutics, Inc. Receives Notice of Allowance in U.S. for an Additional Patent for SLS-007

Seelos Therapeutics Receives Written Notice from The Nasdaq Stock Market LLC Regarding Minimum Bid Price Requirement

Seelos Therapeutics, Inc., Annual General Meeting, May 20, 2022

Founder recently bought €51k worth of stock

Seelos Therapeutics, Inc. Announces Dosing of the First Participants in a Registrational Phase II/III Trial of SLS-005 in Amyotrophic Lateral Sclerosis on the HEALEY ALS Platform

Seelos Therapeutics, Inc. announced that it has received $20 million in funding from The Lind Partners, LLC

High number of new and inexperienced directors

High number of new and inexperienced directors

High number of new and inexperienced directors

Director Judith Dunn has left the company

Seelos Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $60.000004 million.

Seelos Therapeutics, Inc. Announces Positive Data from the Open-Label Study of SLS-002

Seelos Therapeutics Announces Completion of Open-Label Patient Enrollment of Proof of Concept Study of SLS-002 (Intranasal Racemic Ketamine) for Acute Suicidal Ideation and Behavior in Patients with Major Depressive Disorder

Seelos Therapeutics Announces Amendment of SLS-002 Agreement to Repurchase a Significant Portion of Royalties for SLS-002 (Intranasal Racemic Ketamine Program)

New 90-day high: €3.20

New 90-day high: €1.60

Seelos Therapeutics, Inc. Announces Dosing of the First Patients in its Registrational Proof of Concept Study of SLS-002 (Intranasal Racemic Ketamine) for Acute Suicidal Ideation and Behavior

Seelos Therapeutics Regains Compliance with Minimum Bid Price Requirement

New 90-day high: €1.33

Seelos Therapeutics, Inc. announced that it has received $10 million in funding from The Lind Partners, LLC

New 90-day high: €0.93

Revenue in line with expectations

Seelos Therapeutics, Inc. Announces Sponsored Research Agreement with Duke University for Gene Therapy Studies of SLS-004 in Parkinson's Disease

Seelos Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $7.00335 million.

New 90-day low - €0.56

New 90-day low - €0.70

Seelos Therapeutics, Inc.(NasdaqCM:SEEL) dropped from Russell Microcap Value Index

Shareholder Returns

Price Volatility

About the Company

Seelos Therapeutics, Inc. Fundamentals Summary

8.8x

-0.3x

Earnings & Revenue